Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
The Nexbiome Therapeutics company patent portfolio operates within the Biotechnology & Pharmaceuticals technology area. Current prosecution activity is characterized by 1 pending office action, which is distributed across 1 distinct examiner and 1 distinct art unit. This concentration suggests a focused technical scope for the entity's intellectual property development.
The busiest examiner for this portfolio is ZINGARELLI, SANDRA, who is currently managing 1 busiest examiner pending office action. Since there is 1 pending office action in total, ZINGARELLI, SANDRA is responsible for the entirety of the active prosecution workload. This activity is localized within 1 distinct art unit, indicating that the legal strategy is confined to a specific niche within the Biotechnology & Pharmaceuticals sector.
Practitioners should note that with only 1 distinct examiner involved, the outcome of the current pending office action will significantly impact the overall success of the portfolio. The alignment of 1 pending office action with 1 distinct art unit reflects a streamlined interaction with the patent office. This approach allows for a dedicated focus on securing specific assets without the complexity of multiple simultaneous examinations.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| ZINGARELLI, SANDRA | 1 | 6.9% | +46.3% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17523352 | COMPOSITIONS FOR TREATING CANDIDIASIS INFECTIONS | ZINGARELLI, SANDRA | 55d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17523352 | COMPOSITIONS FOR TREATING CANDIDIASIS INFECTIONS | ZINGARELLI, SANDRA | 55d |
| Art Unit | Apps |
|---|---|
| 1653 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17523352 | COMPOSITIONS FOR TREATING CANDIDIASIS INFECTIONS | ZINGARELLI, SANDRA | 1653 | §103 | Final Rejection | 55d | Pending | Nov 10, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial